Please assess the completion status of the following clinical trial:

Trial Title: Felzartamab in Late Antibody-Mediated Rejection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Voluntary written informed consent~* Age \>18 years (maximum: 80 years)~* Functioning living or deceased donor allograft after ≥180 days post-transplantation~* eGFR ≥20 ml/min/1.73 m2 (CKD-EPI formula)~* HLA class I and/or II antigen-specific antibodies (preformed and/or de novo DSA).~* Active or chronic/active ABMR (±C4d in PTC) according to the Banff 2019 classification~* Molecular ABMR score (MMDx) ≥0.2~Exclusion Criteria:~* Patients actively participating in another clinical trial~* Age ≤18 years~* Female subject is pregnant or lactating or not on adequate contraceptive therapy~* ABO-incompatible transplant~* Index biopsy results:~* T-cell-mediated rejection classified Banff grade ≥I~* De novo or recurrent severe thrombotic microangiopathy~* Polyoma virus nephropathy~* De novo or recurrent glomerulonephritis~* Acute rejection treatment ≤3 month before screening~* Previous treatment with other CD38 monoclonal antibodies (e.g. daratumumab)~* Previous treatment with other immunomodulatory monoclonal/polyclonal antibodies (e.g. CD20 Ab rituximab, IL-6/IL-6R Ab) ≤3 months before study treatment~* Total bilirubin \>2×the upper limit of normal \[ULN\], alanine transaminase and aspartate aminotransferase \>2·5×ULN~* Haemoglobin \<8 g/dL~* Thrombocytopenia: Platelets \<100 G/L~* Leukopenia: Leukocytes \<3 G/L~* Neutropenia: Neutrophils \< 1.5 G/L~* Hypogammaglobulinemia: Serum IgG \<400 mg/dL~* Active viral, bacterial or fungal infection precluding intensified immunosuppression~* Active malignant disease precluding intensified immunosuppressive therapy~* Latent or active tuberculosis (positive QuantiFERON-TB-Gold test)~* Administration of a live vaccine within 6 weeks of screening~* History of alcohol or illicit substance abuse~* Serious medical or psychiatric illness likely to interfere with participation in the study

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Felzartamab (Type: ACTIVE_COMPARATOR): 9 doses of felzartamab as an intravenous infusion over 6 treatment cycles at 28 days each. Dosing occurs every week in cycle 1 and every four weeks in cycles 2-6.
- Placebo (Type: PLACEBO_COMPARATOR): 9 doses of placebo as an intravenous infusion over 6 treatment cycles at 28 days each. Dosing occurs every week in cycle 1 and every four weeks in cycles 2-6.

Based on this trial design, predict the completion outcome and termination type (if applicable).